| ￥5800 | |
| Z04648-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 34.81 kDa | ||||||
| Apparent Molecular Weight | Due to enzyme lysis and glycosylation, the protein migrates to 38-48 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS, 0.2M Arginine (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
APLN hFc Chimera[Biotin], Avi, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Macrophages play key roles during cardiovascular diseases (CVD) and their related complications.Apelin (APLN) is a key molecule, whose roles during CVD have been documented previously. Therefore, it has been hypothesized that APLN may perform its roles via modulation of macrophages. |
| Synonyms | Apelin;APJ endogenous ligand;APEL |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
